Biorestorative Therapies (BRTX) Projected to Post Earnings on Thursday

Biorestorative Therapies (NASDAQ:BRTX) is anticipated to release its Q4 2025 results after the market closes on Thursday, March 26th. Analysts expect Biorestorative Therapies to post earnings of ($0.37) per share and revenue of $0.15 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Biorestorative Therapies Stock Down 9.2%

BRTX stock opened at $0.23 on Thursday. Biorestorative Therapies has a 52-week low of $0.19 and a 52-week high of $2.10. The stock has a market cap of $2.07 million, a price-to-earnings ratio of -0.16 and a beta of 0.47. The business has a fifty day moving average of $0.66 and a two-hundred day moving average of $1.12.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Biorestorative Therapies

Several institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in Biorestorative Therapies in the third quarter valued at approximately $152,000. DRW Securities LLC purchased a new position in shares of Biorestorative Therapies during the fourth quarter worth $55,000. Finally, Virtu Financial LLC grew its stake in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares in the last quarter. Institutional investors and hedge funds own 69.38% of the company’s stock.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.